As of 2025-07-04, the Intrinsic Value of Allarity Therapeutics A/S (ALLR.ST) is 0.23 SEK. This ALLR.ST valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.55 SEK, the upside of Allarity Therapeutics A/S is -85.3%.
Based on its market price of 1.55 SEK and our intrinsic valuation, Allarity Therapeutics A/S (ALLR.ST) is overvalued by 85.3%.
Range | Selected | Upside | ||
a | ||||
Peter Lynch Fair Value | 0.23 - 0.23 | 0.23 | -85.26% | |
P/E Multiples | (11.52) - (5.92) | (10.77) | -795.0% |
Range | Selected | Upside | ||
a | ||||
Bavarian Nordic A/S | 80.94 - 282.51 | 127.82 | -24.6% | |
Saniona AB | 19.59 - 38.04 | 25.73 | 153.7% | |
Plant Advanced Technologies PAT SA | 14.64 - 17.08 | 15.83 | 65.3% | |
Genomed SA | 17.09 - 27.4 | 20.62 | -18.8% |
Market Cap (mil) | 626 |
Beta | 1.07 |
Outstanding shares (mil) | 404 |
Enterprise Value (mil) | 574 |
Market risk premium | 5.2% |
Cost of Equity | 7.65% |
Cost of Debt | 5% |
WACC | 7.6% |